Heidelberg Pharma AG

Share Issue/Capital Change • Mar 18, 2015

News Details

Ad-hoc | 18 March 2015 20:33

WILEX AG plans rights issue using authorised capital supported by main shareholder dievini

WILEX AG / Key word(s): Capital Increase

18.03.2015 20:33

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---

Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz
(German Securities Trading Act)

• Not for distribution, publication or transmission
  in the USA, Canada, Japan and Australia -

WILEX AG plans rights issue using authorised capital supported by main
shareholder dievini

Munich, Germany, 18 March 2015 - The Executive Management Board of WILEX AG
(ISIN DE000A11QVV0 / WL6 / FSE) today resolved, with the approval of the
Supervisory Board, to increase the Company's share capital using authorised
capital from EUR 7,818,876.00 by up to EUR 1,486,732.00 to up to EUR
9,305,608.00 by issuing up to 1,486,732 new no-par value shares with a
pro-rata interest in capital of EUR 1.00 each and full entitlement to
dividends effective 1 December 2014 in return for cash contributions.

The new shares will be offered to shareholders at a 21:4 ratio by means of
an indirect subscription right by Baader Bank AG, Unterschleissheim. Hence,
shareholders will be entitled to subscribe for 4 new shares for each 21
existing shares held. One of the existing shareholders has undertaken to
waive its subscription rights with respect to 13,533 shares in order to
ensure an even subscription ratio.

The subscription period will begin on 20 March 2015 and will end on 07
April 2015 at 03.00 pm. The subscription price is fixed at EUR 2.80. There
will be no organised trading in subscription rights.

Any new shares not subscribed for as a result of the offer may be purchased
by shareholders only - also at the subscription price - as part of an
additional subscription for shares. Binding offers for such additional
subscriptions must be submitted within the subscription period.

The main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf,
Germany, has agreed to exercise its subscription rights and take over
shares as part of an additional subscription, if applicable. In total,
dievini is committed to provide the company with up to EUR 5 million.

WILEX AG plans to use the expected gross proceeds from the rights issue of
EUR 4.16 million to finance the further development of the ADC-technology
in particular the GMP transfer of the drug production as well as to enhance
its equity.

The new shares are to be admitted to trading in the regulated market on the
Frankfurt stock exchange (Prime Standard) without the publication of an
offering prospectus. The new WILEX shares are due to be included in the
existing listing on the Frankfurt stock exchange on 13 April 2015.

For further details on the rights issue, please see the subscription offer
provisionally planned to be published in the Federal Gazette
(www.bundesanzeiger.de) on 19 March 2015 and on the website of WILEX AG
(www.wilex.com).

Important notes

This ad hoc release does not constitute either an offer to sell or an
invitation to buy securities. In particular, this document does not
constitute an offer to sell securities or a solicitation of an offer to buy
securities in the United States of America. The shares of WILEX AG (the
"Shares") may not be offered or sold in the United States of America or to
or for the account or benefit of "U.S. persons" (as defined in Regulation S
under the U.S. Securities Act of 1933, as amended (the "Securities Act")),
unless they have been registered or are exempt from registration under the
Securities Act. The Shares have not been and will not be registered under
the Securities Act. There will be no public offer of Shares in the United
States of America.

---

Information and Explaination of the Issuer to this News:

About WILEX and Heidelberg Pharma
WILEX AG is a biopharmaceutical company which has a ready for partnering
portfolio of antibody-based diagnostic and therapeutic Phase III product
candidates for the detection and targeted treatment of clear cell renal
cell carcinoma. Research and development focus on the operations of its
subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances
the development of the innovative platform technology for antibody drug
conjugates (ADC technology) and provides pre-clinical drug discovery and
development services. WILEX is listed at the Frankfurt Stock Exchange: ISIN
DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at
http://www.wilex.com/.

Contact

WILEX AG IR/PR support
Sylvia Wimmer MC Services AG
Corporate Communications Katja Arnold (CIRO)
Tel.: +49 (0)89-41 31 38-29 Executive Director
Email: investors[at]wilex.com Tel.: +49-89-210 228-40
Grillparzerstr. 10, 81675 Munich, Email: katja.arnold[at]mc-
Germany services.eu

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will', 'should', 'future', 'potential' or similar expressions or by
a general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward- looking statements to reflect future
events or developments.

18.03.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE000A11QVV0
WKN: A11QVV
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart

End of Announcement DGAP News-Service

---